Chica­go AI drug dis­cov­ery shop Evozyne nabs $81M in bid to make new pro­teins

Chica­go start­up Evozyne has raised $81 mil­lion fol­low­ing a gen­er­a­tive AI col­lab­o­ra­tion with Nvidia an­nounced ear­li­er this year.

The three-year-old start­up is cre­at­ing new pro­teins to use for ther­a­peu­tics and car­bon cap­ture and has al­ready part­nered with Take­da. Evozyne an­nounced in April 2022 that it would help cre­ate pro­teins for the Japan­ese phar­ma to po­ten­tial­ly use in gene ther­a­pies, span­ning up to four rare dis­ease tar­gets. But it’s al­so look­ing to de­vel­op its own pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER